

An Clinical Study Evaluating the Safety, Tolerability, and efficacy of HG005 in Stargardt Disease

NCT07063251

Status	RECRUITING
Phase	Early Phase 1
Sponsor	HuidaGene Therapeutics Co., Ltd.
Enrollment	6 participants

Key Eligibility Criteria

Inclusion (6)

- Patient e 6 and d17 years at the time of signing informed consent, with clinical diagnosis of Stargardt disease;
- At least one ABCA4 allele on each chromosome;
- Both eyes must have well-defined macular atrophic lesions consistent with the diagnosis of Stargardt macular dystrophy.
- Meet visual acuity criteria based on ETDRS letter chart
- Subject must agree to contraception during the study.

... and 1 more (see full listing online)

Exclusion (9)

- Presence of active intraocular inflammation or uveitis history in either eye;
- Presence of ocular or periocular infection history in either eye within 2 weeks prior to selection;
- History or presence of corneal dystrophy in the study eye;
- History of HIV or hepatitis A, B, or C infection;
- Previous treatment with any gene therapy or cell therapy (e.g., stem cell transplantation);

... and 4 more (see full listing online)

Locations (1 total)

Eye & ENT Hospital of Fudan University, Shanghai, China